BCD-135 Monoclonal Antibody PD-L1 Binding Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for enhancing T-cell function and addressing T-cell dysfunction associated with PD-L1-mediated disorders, such as cancer, are limited in efficacy and specificity, particularly in targeting PD-L1 for immunotherapy.
Innovation Solution
A monoclonal antibody, BCD-135, specifically binds to PD-L1, comprising heavy and light chain variable domains with defined amino acid sequences, designed to inhibit PD-L1 biological activity and enhance T-cell function, potentially used in combination with other therapeutically active compounds for treating various cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for enhancing T-cell function are used, then T-cell dysfunction associated with PD-L1-mediated disorders can be addressed, but the treatments are limited in efficacy and specificity
Solution Approach 1:
The patent employs an antibody as an intermediary molecule that specifically binds to PD-L1, blocking its interaction with PD-1 receptors on T-cells. This intermediary approach allows indirect modulation of the PD-1/PD-L1 pathway, enhancing T-cell function without directly manipulating the receptor-ligand interaction, thereby improving efficacy while maintaining treatment simplicity
Solution Approach 2:
The invention changes the binding parameters by developing an antibody with specific affinity and specificity for PD-L1. By optimizing the antibody's binding characteristics (KD, specificity), the treatment achieves higher efficacy in blocking PD-L1-mediated T-cell suppression while maintaining a straightforward therapeutic approach
2Reliability
If current treatments for enhancing T-cell function are used, then T-cell dysfunction can be addressed, but the treatments lack specificity in targeting PD-L1
Solution Approach 1:
The antibody serves as a highly specific intermediary that selectively binds to PD-L1, distinguishing it from other ligands such as PD-L2. This specificity is achieved through the antibody's complementary determining regions (CDRs) that are structurally complementary to epitopes on PD-L1, enabling precise targeting without complex multi-component systems
Solution Approach 2:
The invention applies local quality by designing the antibody's binding site with specific amino acid sequences and structural features that match PD-L1's epitope. This localized structural complementarity ensures high specificity for PD-L1 over other similar molecules, achieving precise targeting through localized molecular recognition rather than global structural complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The BCD-135 antibody effectively inhibits PD-L1, enhancing T-cell function and immune responses, offering a targeted approach for treating PD-L1-mediated disorders like cancer by boosting T-cell activity and immune recognition of tumors.
Implementation Method 1
A monoclonal antibody, BCD-135, specifically binds to PD-L1, comprising heavy and light chain variable domains with defined amino acid sequences
Data Source
AI summary
The present invention relates to the field of biotechnology and provides antibodies that specifically binds to PD-L1. The invention also relates to DNA encoding said antibodies, to corresponding expression vectors and to methods of producing, and to methods of treatment using said antibodies.